Is Recursion stock $RXRX a buy? 📊 Smart money analysis in biotechnology pharmaceuticals stocks

📊 Recursion Pharmaceuticals is developing treatments across areas like Oncology Neuroscience, and Immunology using technology and AI. It’s been in consolidation since early February, but do we know which way it will break out? Is now an opportunity to buy or is it setting up for a bull trap? Before investing in Recursion Pharmaceuticals, watch this video first.

Recursion Pharmaceuticals is a clinical-stage biotech company that uses artificial intelligence, machine learning, automation, and massive biological datasets to speed up the drug discovery process. The company’s goal is to identify potential new medicines faster and more efficiently than traditional pharmaceutical research methods.

Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion combines software engineering, biology, chemistry, and AI into what it calls the “Recursion OS” — a platform designed to analyze millions of experiments and uncover patterns in human disease.

On the bullish side, large institutional investors including Vanguard, BlackRock, and ARK Invest continue holding significant positions in the company. Institutional ownership remains extremely high, with an estimated hundreds of millions of dollars flowing into the stock over the past two years.

But despite those long-term bets, short sellers are aggressively targeting the stock. Short interest has climbed to roughly one-third of the company’s float, signaling that many hedge funds are betting the company could struggle with commercialization timelines, ongoing cash burn, and future dilution risk.

One of the biggest sentiment hits came after NVIDIA exited its entire position in Recursion Pharmaceuticals, triggering concerns across Wall Street that the company may be losing some of its AI momentum narrative.
Within the healthcare sector, smart money continues flowing toward areas like obesity drugs, oncology, precision medicine, and profitable large-cap pharmaceutical companies. Meanwhile, capital is moving away from speculative early-stage biotech firms with high cash burn and limited revenue visibility — a category many investors still place Recursion within.

The bottom line: Wall Street sees Recursion Pharmaceuticals as a high-risk, high-reward AI biotech story. Long-term investors are cautiously accumulating shares, while hedge funds continue heavily betting against the stock. Future clinical data, partnership expansion, and commercialization progress will likely determine which side of the trade ultimately wins.

________________________________________
📌 What You’ll Learn in This Video:
• How supply vs. demand dynamics are shaping the market
• Which sectors are leading in demand
• Sectors showing continued selling pressure
• Key industry-level winners & losers over the past 2 weeks
• What our Bottom Finders signals are revealing right now
• Where potential market reversals may be forming
________________________________________
⚙️ About Bottom Finders
Bottom Finders technology presents its findings through the lens of a market maker, encouraging a strategic mindset centered on how a major institution might approach managing a stock. By developing a clear understanding of supply and demand, traders can better align themselves with these forces and follow the flow that ultimately drives market movement. The platform uses advanced algorithms and proprietary indicators like:
• Demand & Supply Metrics
• Net Volume
• Custom OBV (On-Balance Volume)
…to help identify early bottoming opportunities in the market.
________________________________________
🎯 Try It Yourself
Experience our technology FREE — no credit card required.
👉 Visit the Bottom Finders website (www.bottomfinders.com) and start your free trial today.
________________________________________
⚠️ Disclaimer
This content is for informational and educational purposes only and does not constitute financial or investment advice. All investments carry risk. Always do your own research and consult with a licensed financial advisor before making investment decisions.
________________________________________
👍 Support the Channel
If you found this helpful:
✔️ Like the video
✔️ Subscribe for daily market reports
✔️ Turn on notifications so you never miss an update

Видео Is Recursion stock $RXRX a buy? 📊 Smart money analysis in biotechnology pharmaceuticals stocks канала Bottom Finders